Last reviewed · How we verify
Humanized TNFα monoclonal antibody
At a glance
| Generic name | Humanized TNFα monoclonal antibody |
|---|---|
| Also known as | TNFα monoclonal antibody |
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment (PHASE3)
- Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis (PHASE3)
- The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis (PHASE3)
- Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis (PHASE4)
- Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D (EARLY_PHASE1)
- Th17 Responses Evaluated in RA Patients on Inhibitors of TNFα
- A Multicentered Prospective Cohort Study of Chinese IBD Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: